Form F-6EF COMPASS Pathways plc/ADR Filed by: Citibank,N.A./ADR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS)
May 13, 2026 3:34 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "1Q26 R&D was $26.5MM (-11% q/q) and G&A was $16.4MM (+2% q/q). 1Q26 net loss was $91.2MM; EPS was $0.71. End of 1Q26 cash was $466MM; cash is expected to provide runway to 2028, including the anticipated commercial launch of '360 in TRD.
COMP360 Rolling NDA Started, Expected To Complete In Q4 After 26-Week Ph3 COMP006 Data In Early Q3
CMPS... More
BTIG Reiterates Buy Rating on Compass Pathways (CMPS)
May 13, 2026 2:33 PM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $14.00 price target on Compass Pathways (NASDAQ: CMPS)
The analyst comments "Modest update with the new CNPV voucher potentially shortening the final step to approval after the filing is complete. We see that window as variable and mostly based on the political winds - which are strong tailwinds at the moment. The remaining clinical data from PART B of the 006 trial will help define the duration of response for patients after two doses. We see this data as potentially meaningful once there is a... More
